B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)
Study of Cell Markers of Marginal Zone Lymphoma and Other B-cell Chronic Lymphoid Malignancies
Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated). The diagnosis of these malignancies relies on the study of the morphology of tumoral cells and the expression by these cells of several markers, mainly via a technical approach called flow cytometry. Because the markers currently used remain imperfect, additional ones are needed for an accurate diagnosis that affect both prognosis and treatment.
In addition, because numerous markers are used at the diagnosis, there is a need of tools that synthetize the multi-dimensional structure of the data obtained.
The primary purpose of this study is to detect new markers that can be of help for the diagnosis of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies.
The secondary purpose of this study is to obtain a statistical algorithm that allow a good prediction of the different sub-types of chronic B-cell malignancies mainly using the results of flow cytometry.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Laurent MAUVIEUX, MD, PhD
- Phone Number: 33 3 88 12 75 27
- Email: laurent.mauvieux@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Hematology Laboratory - Strasbourg University Hospitals
-
Contact:
- Laurent MAUVIEUX, MD, PhD
- Phone Number: 33 3 88 12 75 27
- Email: laurent.mauvieux@chru-strasbourg.fr
-
Principal Investigator:
- Laurent MAUVIEUX, MD, PhD
-
Sub-Investigator:
- Laurent MIGUET, MD
-
Sub-Investigator:
- Caroline MAYEUR-ROUSSE, MD
-
Sub-Investigator:
- Thibaut FABACHER, MD
-
Sub-Investigator:
- Ravzan BIZOI
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies
- patients that gave their informed consent for the conservation of blood or bone marrow cells (primary objective 1)
- patients that gave their informed consent for the retrospective use of their clinical and biological data
Exclusion Criteria:
- patients under guardianship or curatorship
- patients who did not gave their consent for the use of their cells and/or data
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Retrospective study of laboratory data from patients with B lymphoid hemopathy, mainly lymphoma in the marginal zone
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Laurent MAUVIEUX, MD, PhD, Hematology Laboratory - Strasbourg University Hospitals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, Lymphoid
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Neoplasms
- Lymphoma
- Leukemia
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell, Marginal Zone
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Hairy Cell
Other Study ID Numbers
Other Study ID Numbers
- 8205
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.